載入中
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
前收盤價
US$10.82
+US$0.24 · +2.27%
盤中時間採用ET。市場資料可能有所延遲。
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
日內區間
目前US$10.82
52週區間
目前US$10.82
盤中時間採用ET。市場資料可能有所延遲。
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis. Established in 2021, MoonLake Immunotherapeutics is based in Zug, Switzerland.
日內區間
目前US$10.82
52週區間
目前US$10.82
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 261.6萬 USD | — | — | — | 4971 USD |
| 毛利 | −261.6萬 USD | — | — | — | −4971 USD |
| 研究與開發 | 2.03億 USD | 1.13億 USD | 3180.19萬 USD | 4204.9萬 USD | 3552.44萬 USD |
| 銷售、一般及管理費用 | 4197.2萬 USD | 3031.98萬 USD | 2232.12萬 USD | 2301.25萬 USD | 1804.77萬 USD |
| 營業費用 | 2.42億 USD | 1.43億 USD | 5412.31萬 USD | 6506.14萬 USD | 5357.2萬 USD |
| 利息支出 | 724.8萬 USD | — | — | — | — |
| 折舊和攤銷 | 261.6萬 USD | 138.47萬 USD | 37萬 USD | 16.48萬 USD | 4971 USD |
| 營業利益 | −2.45億 USD | −1.43億 USD | −5412.31萬 USD | −6506.14萬 USD | −5357.7萬 USD |
| 淨利 | −2.27億 USD | −1.19億 USD | −3600.73萬 USD | −4997.32萬 USD | −5364.36萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$50.00
上漲空間 362.11%報告持有此股票曝險的交易所交易基金。
T. Rowe Capital Appreciation Equity ETFTCAF254.9萬0.03%91.1億 USD0.31%US$43.59+0.90%
Vanguard Health Care ETFVHT203.37萬0.01%220億 USD0.09%US$319.01+1.64%
iShares ESG Aware MSCI USA Small-Cap ETFESML91.64萬0.03%27.28億 USD0.17%US$52.74+0.59%
Nuveen ESG Small-Cap ETFNUSC46.36萬0.04%12.35億 USD0.31%US$49.27+0.57%
T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMED45.07萬1.40%3296.48萬 USD0.44%US$33.8094+2.13%
State Street SPDR S&P International Small Cap ETFGWX40.31萬0.04%9.08億 USD0.40%US$45.56+0.93%
Optimize Strategy Index ETFOPTZ34.79萬0.13%2.71億 USD0.25%US$46.0402+0.66%
Fidelity Nasdaq Composite Index ETFONEQ32.69萬—109.4億 USD0.21%US$107.81+0.63%T. Rowe Capital Appreciation Equity ETFTCAFVanguard Health Care ETFVHTiShares ESG Aware MSCI USA Small-Cap ETFESMLNuveen ESG Small-Cap ETFNUSCT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETFTMEDState Street SPDR S&P International Small Cap ETFGWXOptimize Strategy Index ETFOPTZFidelity Nasdaq Composite Index ETFONEQAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
